Psyence Biomedical Announces Recruitment Of Second Clinical Trial Site For Ongoing Phase IIb Clinical Trial Of Nature-Derived Psilocybin For Adjustment Disorder In Palliative Care
Portfolio Pulse from Benzinga Newsdesk
Psyence Biomedical has announced the recruitment of a second clinical trial site, Empax Center, for its ongoing Phase IIb trial of psilocybin for adjustment disorder in palliative care. The company plans to start recruitment this quarter and release topline data in the second half of 2025.
October 25, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Psyence Biomedical is advancing its Phase IIb clinical trial by recruiting a second site, Empax Center, for its psilocybin treatment for adjustment disorder. Recruitment is set to begin this quarter, with results expected in 2025.
The recruitment of a second clinical trial site indicates progress in Psyence Biomedical's Phase IIb trial, which could positively impact investor sentiment. The announcement of topline data in 2025 provides a timeline for potential results, which is crucial for investors tracking the company's progress.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100